NCT00020878View on ClinicalTrials.gov

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

November 30, 2002

Study Completion Date

May 31, 2009

Conditions
Lung Cancer
Interventions
DRUG

celecoxib

Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00020878 - Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers | Biotech Hunter | Biotech Hunter